General information about company		
Scrip code*	543233	
NSE Symbol*	CHEMCON	
MSEI Symbol*	NOTLISTED	
ISIN*	INE03YM01018	
Name of company	Chemcon Speciality Chemicals Limited	
Type of company	Main Board	
Class of security	Equity	
Date of start of financial year	01-04-2024	
Date of end of financial year	31-03-2025	
Date of board meeting when results were approved	14-05-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	08-05-2025	
Description of presentation currency	INR	
Level of rounding	Lakhs	
Reporting Type	Quarterly	
Reporting Quarter	Fourth quarter	
Nature of report standalone or consolidated	Standalone	
Whether results are audited or unaudited for the quarter ended	Audited	
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited	
Segment Reporting	Single segment	
Description of single segment	Specialty Chemicals	
Start date and time of board meeting	14-05-2025 16:00	
End date and time of board meeting	14-05-2025 16:45	
Whether cash flow statement is applicable on company	Yes	
Type of cash flow statement	Cash Flow Indirect	
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Whether the company has any related party?	Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes	
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA	
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA	
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		

Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		12-02-2025
Indicate Company website link for updated RPT policy of the Company		https://cscpl.com/wp- content/uploads/investors-relations/policies/g- policy-on-dealing-with-related-party- transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		No
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	The disclosure for the default on loans and debt securities not applicable to the company.

	Financial	l Results – Ind-AS	
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-01-2025	01-04-2024
	Date of end of reporting period	31-03-2025	31-03-2025
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated R zero shall be inserted in the said column.	esults, if the company has no	figures for 3 months / 6 months end
1	Income		
	Revenue from operations	5488.76	20740.18
	Other income	318.44	1429.27
	Total income	5807.2	22169.45
2	Expenses		
(a)	Cost of materials consumed	3679.42	11708.17
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-283.97	337.03
(d)	Employee benefit expense	507.92	1947.74
(e)	Finance costs	83.54	349.26
(f)	Depreciation, depletion and amortisation expense	273.09	1051.16
(g)	Other Expenses		
1	Other expenses	1007.43	3461.45
	Total other expenses	1007.43	3461.45
	Total expenses	5267.43	18854.81
3	Total profit before exceptional items and tax	539.77	3314.64
4	Exceptional items	0	0
5	Total profit before tax	539.77	3314.64
6	Tax expense		
7	Current tax	144.41	850.71
8	Deferred tax	0.76	18.72
9	Total tax expenses	145.17	869.43
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	394.6	2445.21
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0

		ssadasdasdasisalai.		
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	394.6	2445.21	
17	Other comprehensive income net of taxes	-9.42	-20.2	
18	Total Comprehensive Income for the period	385.18	2425.01	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	3663.07	3663.07	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve		43977.78	
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	1.08	6.68	
	Diluted earnings (loss) per share from continuing operations	1.08	6.68	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued oper	ations)		
	Basic earnings (loss) per share from continuing and discontinued operations	1.08	6.68	
	Diluted earnings (loss) per share from continuing and discontinued	1.08	6.68	
	operations			
24	Debt equity ratio			Textual Information(1)
24 25				
	Debt equity ratio			Information(1) Textual

	Text Block
Textual Information(4)	1 These Financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 and read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. 2 The above results have been reviewed by Audit Committee and the Board of Directors have approved the above results at their meeting held on May 14, 2025. The above results were audited by the Statutory Auditors. 3 The Company is in the business of manufacturing of Specialty Chemicals. There is only one reportable segment in accordance with Ind AS 108 - Operating Segments. 4 Figures of corresponding previous year/period(s) have been regrouped /rearranged wherever necessary, to make them comparable. 5 The Company has no subsidiary/ associate / Joint Venture Company, as on March 31, 2025. 6 The figures of 3 months ended March 31, 2025 and corresponding 3 months ended on March 31, 2024 are the balancing figures between the audited figures in respect of full financial year and year to date figures up to the third quarter of the respective financial years. 7 The above Financial Results of the Company are available on the Company's website www.cscpl.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

	Statement of Asset and Liabilities	
	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	14867.0
	Capital work-in-progress	3986.2
	Investment property	
	Goodwill	
	Other intangible assets	0.8
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	25.2
	Trade receivables, non-current	
	Loans, non-current	
	Other non-current financial assets	4255.6
	Total non-current financial assets	4280.8
	Deferred tax assets (net)	
	Other non-current assets	354.7
	Total non-current assets	23489.7
2	Current assets	
	Inventories	8610.5
	Current financial asset	
	Current investments	978.6
	Trade receivables, current	5173.7
	Cash and cash equivalents	712.2
	Bank balance other than cash and cash equivalents	13439.5
	Loans, current	
	Other current financial assets	709.3
	Total current financial assets	21013.6

ssadasdasdastsafaf.html	
Current tax assets (net)	24.23
Other current assets	2255.8
Total current assets	31904.19
Non-current assets classified as held for sale	0
4 Regulatory deferral account debit balances and related deferred tax Assets	0
Total assets	55393.98
Total current assets	31904.19
3 Non-current assets classified as held for sale	0
4 Regulatory deferral account debit balances and related deferred tax Assets	0
Total assets	55393.98
Equity and liabilities	
1 Equity	
Equity attributable to owners of parent	
Equity share capital	3663.07
Other equity	46402.79
Total equity attributable to owners of parent	50065.86
Non controlling interest	
Total equity	50065.86
2 Liabilities	
Non-current liabilities	
Non-current financial liabilities	
Borrowings, non-current	18.63
Trade Payables, non-current	
(A) Total outstanding dues of micro enterprises and small enterprises	0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
Total Trade payable	0
Other non-current financial liabilities	0
Total non-current financial liabilities	18.63
Provisions, non-current	79.14
Deferred tax liabilities (net)	461.74
Deferred government grants, Non-current	0
Other non-current liabilities	0
Total non-current liabilities	
Current liabilities	
Current financial liabilities	
Borrowings, current	2450.36
Trade Payables, current	2430.30
(A) Total outstanding dues of micro enterprises and small enterprises	11.4
(A) Total outstanding dues of fine to emerprises and small enterprises	11.4

(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1620.59
Total Trade payab	e 1631.99
Other current financial liabilities	420.63
Total current financial liabilitie	s 4502.98
Other current liabilities	236.71
Provisions, current	28.92
Current tax liabilities (Net)	0
Deferred government grants, Current	0
Total current liabilitie	s 4768.61
3 Liabilities directly associated with assets in disposal group classified as held for sale	0
4 Regulatory deferral account credit balances and related deferred tax liability	0
Total liabilitie	s 5328.12
Total equity and liabilitie	s 55393.98
Disclosure of notes on assets and liabilities	Textual Information(1)

	Other Comprehensive Income				
	Date of start of reporting period	01-01-2025	01-04-2024		
	Date of end of reporting period	31-03-2025	31-03-2025		
	Whether results are audited or unaudited	Audited	Audited		
Nature of report standalone or consolidated		Standalone	Standalone		
	Other comprehensive income [Abstract]				
1	Amount of items that will not be reclassified to profit and loss				
1	Income tax relating to items that will not be reclassified to profit or loss	-12.59	-26.99		
	Total Amount of items that will not be reclassified to profit and loss	-12.59	-26.99		
2	Income tax relating to items that will not be reclassified to profit or loss	-3.17	-6.79		
3	Amount of items that will be reclassified to profit and loss				
	Total Amount of items that will be reclassified to profit and loss				
4	Income tax relating to items that will be reclassified to profit or loss				
5	Total Other comprehensive income	-9.42	-20.20		

	Cash flow statement, indirect	
	Particulars	Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	3314.64
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	349.26
	Adjustments for decrease (increase) in inventories	-2449.33
	Adjustments for decrease (increase) in trade receivables, current	3030.87
	Adjustments for decrease (increase) in trade receivables, non-current	(
	Adjustments for decrease (increase) in other current assets	-75.74
	Adjustments for decrease (increase) in other non-current assets	
	Adjustments for other financial assets, non-current	(
	Adjustments for other financial assets, current	247.72
	Adjustments for other bank balances	(
	Adjustments for increase (decrease) in trade payables, current	437.4
	Adjustments for increase (decrease) in trade payables, non-current	
	Adjustments for increase (decrease) in other current liabilities	-123.1
	Adjustments for increase (decrease) in other non-current liabilities	
	Adjustments for depreciation and amortisation expense	1051.1
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	1
	Adjustments for provisions, current	27.6
	Adjustments for provisions, non-current	1
	Adjustments for other financial liabilities, current	-131.9
	Adjustments for other financial liabilities, non-current	1
	Adjustments for unrealised foreign exchange losses gains	-22
	Adjustments for dividend income	
	Adjustments for interest income	1296.8
	Adjustments for share-based payments	
	Adjustments for fair value losses (gains)	-2.9
	Adjustments for undistributed profits of associates	(

	ssadasdasdasisalai.nimi	
	Other adjustments for which cash effects are investing or financing cash flow	-6.24
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	-34.37
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	1001.29
	Net cash flows from (used in) operations	4315.93
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	264.23
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	4051.7
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	22.72
	Purchase of property, plant and equipment	957.21
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	4.36
	Purchase of other long-term assets	1000.98
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0

	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	1296.82
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-1257.22
	Net cash flows from (used in) investing activities	-1891.51
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	1804.96
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	349.26
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	-2154.22
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	5.97
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	-0.7
	Net increase (decrease) in cash and cash equivalents	5.27
	Cash and cash equivalents cash flow statement at beginning of period	707.02
	Cash and cash equivalents cash flow statement at end of period	712.29

					Fo	rmat for Dis	sclosure of Re	lated Par	ty Transa	ctions (ap	plicable o	only for h	alf-year	ly filing	s i.e., 2nd
															Additional inter-corpc
	entity /subside	ne party (listed diary) entering transaction	Deta	ils of the counterp	party			Value of the related		Value of	Date of		In case are due party as of the tra	to either a result	In case an incurred to corpor
Sr. No.	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	Type of related party transaction	Details of other related party transaction	party	Remarks on approval by audit committee	the related party transaction ratified by the audit committee	Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	Opening balance	Closing balance	Nature of indebtednes (loan/issuance of debt/ any other etc.)
1	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Kamalkumar Rajendra Aggarwal	ABMPA5842R	Chairman & Managing Director	Remuneration			-			82	52.24	27.26	
2	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Naresh Vijaykumar Goyal	ACKPG9040N	Joint Managing Director	Remuneration			-			48	11.83	30.13	
3	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Navdeep Naresh Goyal	AQPPG5045C	Whole-time Director	Remuneration			-			2	44.07	4.07	

4	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Rajesh Chimanlal Gandhi	ABYPG8719M	Whole-time Director and Chief Financial Officer	Remuneration		-		24.3	3.03	3.03	
5	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr Himanshu Prafulchandra Purohit	AJAPP4831D	Whole-time Director	Remuneration		-		24.3	3.03	3.03	
6	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Shahilkumar Maheshbhai Kapatel	BWOPK1368J	Company Secretary & Compliance Officer	Remuneration		-		4.77	0.64	1.02	
7	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Bharat Chunilal Shah	AFVPS3565E	Independent Director	Any other transaction	Director Sitting Fees	-		0.2	0.68	0.05	

					000,00	suasuasisaia							
8	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Ms. Neelu Atulkumar Shah	AGUPS0211R	Independent Director	Any other transaction	Director Sitting Fees	-		0.4	0.63	0.18	
9	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Pankaj Amritlal Shah	AFMPS4268R	Independent Director	Any other transaction	Director Sitting Fees	-		0.15	0.5	0	
10	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Lalit Ramniklal Mehta	AAUPM0018Q	Independent Director	Any other transaction	Director Sitting Fees	-		0.2	0.36	0.09	
11	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Lalit Devidutt Chaudhary	ABZPC4957C	Independent Director	Any other transaction	Director Sitting Fees	-		0.1	0	0	
12	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Ketan Bhailal Shah	AMXPS8554L	Independent Director	Any other transaction	Director Sitting Fees	-		0.2	0	0.18	

					000,00	suasuasisaia								
13	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Mr. Kamalkumar Rajendra Aggarwal	ABMPA5842R	Chairman & Managing Director	Any other transaction	Rent expense	12	-		0.9	0.16	0.16	
14	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Ms. Minal Kamal Aggrawal	ABOPA4228R	Relative of Key Management Personnel	Any other transaction	Rent expense	12	-		0.9	0.14	0.14	
15	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Ms. Puja Sarman Shah	AEEPG1560M	Relative of Key Management Personnel	Any other transaction	Rent expense	12	-		0.9	0.14	0.14	
16	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Ms. Parul Utssav Gupta	AKIPG2366H	Relative of Key Management Personnel	Any other transaction	Rent expense	12	-		0.9	0.14	0.14	

					-	suasuasisaid							
17	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Super Chemical Industries	AATFS8165K	Entities over which Key Management Personnel or their Relative have significant influence or Control		2000	-		54.53	15.21	15.45	
18	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Shivam Petrochem Industries	AAUFS1369J	Entities over which Key Management Personnel or their Relative have significant influence or Control		2000	-		6.48	235.36	242.24	
19	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Dtech Products Private Limited	AAHCD5639E	Entities over which Key Management Personnel or their Relative have significant influence or Control	or services	2000	-		152.63	0	180.1	

				ooaaa	saasaasisala							
20	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Dtech Products Private Limited	Entities over which Key Management Personnel or their Relative have significant influence or Control	Purchase of goods or services	2000			49.33	-130.07	39.36	
21	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Medicap Healthcare Limited	Entities over which Key Management Personnel or their Relative have significant influence or Control	Purchase of goods or services	2000	•		145.93	0	0.52	

						Jaabaabibaia							
22	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Medicap Industries	AAUFS1369J	Entities over which Key Management Personnel or their Relative have significant influence or Control	Purchase of goods or services	2000	-		331.11	-0.47	0	
23	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Shivam Petrochem Industries	ABTFM9258N	Entities over which Key Management Personnel or their Relative have significant influence or Control	Purchase of goods or services	2000	-		0.22	0	0	
24	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Supertech Fabrics Private Limited	AAVCS4872Q	Entities over which Key Management Personnel or their Relative have significant influence or Control	Purchase of goods or services	2000	-		0.58	0	0	
25	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Dtech Products Private Limited	AAHCD5639E	Entities over which Key Management Personnel or their Relative have significant influence or Control	Purchase of fixed assets	2000	-		153.2	0	29.02	

26	CHEMCON SPECIALIT CHEMICAL LIMITED	Z . A A C C C 722 A	Medicap Healthcare Limited		Entitics over which Key Management Personnel or their Relative have significant influence or Control		Reimbursement of expenses Received	2000	-		0.01	1.62	0	
27	CHEMCON SPECIALIT CHEMICAL LIMITED	AAACG6722A	Medicap Healthcare Limited	AALCM1556H	Entities over which Key Management Personnel or their Relative have significant influence or Control	Any other transaction	Reimbursement of expenses Paid	2000	-		0.56	0	0	

						suasuasisaic								
28	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	Dtech Products Private Limited	AAHCD5639E	Entities over which Key Management Personnel or their Relative have significant influence or Control	Any other transaction	Reimbursement of expenses Paid	2000	-		1.18	0	0	
29	CHEMCON SPECIALITY CHEMICALS LIMITED	AAACG6722A	KASR Healthcare Private Limited	AAKCK2894F	Entities over which Key Management Personnel or their Relative have significant influence or Control	Any other transaction	Reimbursement of expenses Received	2000	-		0.34	0	0.34	
Total value of transaction during the reporting period											1086.32			

	Details of Impact of Audit Qualifica	ntion	
Whether re	sults are audited or unaudited	Audited	
Declaration	of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion	
Auditor's o	pinion		
declares tha	pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company at its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the tandalone results	Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Shah Mehta & Bakshi	Yes	31-07-2025